Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apalutamide in Low Risk Prostate Cancer
NCT03088124Phase 2Completed
- Sponsor
- Institut Paoli-Calmettes
- Start
- Apr 2017
- Primary completion
- Oct 2024
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of apalutamide in prostate cancer (PCa), sponsored by Institut Paoli-Calmettes. Started Apr 2017; status: completed.
02
Drugs
apalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03088124.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03088124.